期刊文献+

神经纤毛蛋白-1(NRP-1)在原发免疫性血小板减少症发病机制中的作用 被引量:2

The involvement of neuropilin-1 in primary immune thrombocytopenia
原文传递
导出
摘要 目的探讨神经纤毛蛋白-1(NRP-1)在调节性T细胞(Treg)上的表达与其配体信号素3A(Sema3A)、转化生长因子β1(TGF-β1)以及1型辅助T细胞(Th1)和2型辅助T细胞(Th2)之间平衡的关系。方法纳入2014年3月至2015年5月就诊的62例ITP患者(新诊断ITP 33例、慢性ITP 29例),以同期30名健康体检者作为正常对照组。流式细胞术检测Treg细胞NRP-1表达,酶联免疫吸附法(ELISA)检测血浆Sema3A、TGF-β1、IFN-γ和IL-4水平,实时聚合酶链式反应(RT-PCR)检测外周血NRP-1、Sema3A、TGF-β1 mRNA表达水平。分别采用单因素方差和独立样本t检验进行三组间和两组间比较,用Spearman相关系数评估NRP-1、Sema3A、TGF-β1 mRNA表达的相关性。结果与慢性ITP组和正常对照组比较,新诊断ITP组Treg细胞NRP-1表达降低[分别为(0.15±0.03)%、(0.33±0.15)%、(0.46±0.06)%,P<0.01],血浆Sema3A水平升高[分别为(8.10±1.32)μg/L、(7.41±1.30)μg/L、(2.88±0.82)μg/L,P<0.01],血浆TGF-β1水平降低[分别为(16.50±3.36)μg/L、(35.17±10.26)μg/L、(41.00±10.02)μg/L,P<0.01],血浆IFN-γ水平升高[分别为(17.21±2.80)ng/L、(10.23±1.59)ng/L、(8.18±3.27)ng/L,P<0.01],Th1/Th2(IFN-γ/IL-4)比值升高(分别为1.29±0.30、0.72±0.16、0.61±0.27,P<0.01)。新诊断ITP、慢性ITP组NRP-1、Sema3A mRNA的表达均低于正常对照组(P<0.01)。新诊断ITP组NRP-1 mRNA表达与Sema3A、TGF-β1 mRNA表达均呈正相关。结论NRP-1可能参与ITP的发病机制。 Objective To explore the relationship between the expression of neuropilin-1(NRP-1)on Treg cells and its ligands semaphorins-3A(Sema3A),transforming growth factor-β1(TGF-β1)as well as the balance of type 1 helper T cells(Th1)and type 2 helper T cells(Th2)cells.Methods This study enrolled 62 patients with immune thrombocytopenia(ITP;33 and 29 newly diagnosed and chronic ITP,respectively)from March 2014 to May 2015.Consequently,30 healthy people in the same period were selected as the normal control group.The expression of NRP-1 in Treg cells was detected via flow cytometry.The Sema3A,TGF-β1,IFN-γ,and IL-4 levels in plasma were detected by enzyme-linked immunosorbent assay.The real-time polymerase chain reaction technique was used to detect the mRNA expression levels of NRP-1,Sema3A,and TGF-β1.The one-way analysis of variance and independent sample t-test was used for comparison between three and two groups,respectively.Correlations among the mRNA expression levels of NRP-1,Sema3A,and TGF-β1 were assessed via Spearman correlation coefficients.Results Treg cells in the newly diagnosed ITP group significantly increased compared with those in the chronic ITP and normal control groups.The expression of NRP-1 decreased[(0.15±0.03)%,(0.33±0.15)%,and(0.46±0.06)%;P<0.01],the plasma Sema3A level increased[(8.10±1.32)μg/L,(7.41±1.30)μg/L,and(2.88±0.82)μg/L;P<0.01],and the plasma TGF-β1 level decreased[(16.50±3.36)μg/L,(35.17±10.26)μg/L,and(41.00±10.02)μg/L;P<0.01].Moreover,the level of plasma IFN-γincreased[(17.21+2.80)ng/L,(10.23+1.59)ng/L,and(8.18+3.27)ng/L;P<0.01],and the ratios of Th1/Th2(IFN-γ/IL-4)increased(1.29±0.30,0.72±0.16,and 0.61±0.27;P<0.01).The mRNA expressions of NRP-1 and Sema3A in the newly diagnosed ITP and chronic ITP groups were lower than that in the normal control group(P<0.01).Consequently,the NRP-1 mRNA expression was positively correlated with Sema3A and TGF-β1 mRNA expression in the newly diagnosed ITP group.Conclusion NRP-1 played an essential role in the pathogenesis of ITP.
作者 周虎 杨静宜 徐佩佩 刘柳 丁冰洁 刘建平 李梦娟 宋永平 Zhou Hu;Yang Jingyi;Xu Peipei;Liu Liu;Ding Bingjie;Liu Jianping;Li Mengjuan;Song Yongping(Department of Hematology,The Affiliated Cancer Hospital of Zhengzhou University(Henan Cancer Hospital),Zhengzhou 450008,China;Department of Hematology,First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处 《中华血液学杂志》 CAS CSCD 北大核心 2021年第2期146-150,共5页 Chinese Journal of Hematology
基金 国家自然科学基金(81370615、82070120、81600097)。
关键词 神经纤毛蛋白1 信号素3A 转化生长因子Β1 原发免疫性血小板减少症 Neuropilin-1 Semaphorins-3A Transforming growth factor-β1 Primary immune thrombocytopenia
  • 相关文献

二级参考文献28

  • 1ProvanD, StasiR, NewlandAC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia[J]. Blood,2010,115(2):168-186.
  • 2NeunertC, LimW, CrowtherM, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia[J]. Blood,2011,117(16):4190-4207.
  • 3British Committee for Standards in Haematology General Haematology Task Force. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy[J]. Br J Haematol,2003,120(4):574-596. doi:10.1046/j.1365-2141.2003.04131.x.
  • 4WeiY, JiXB, WangYW, et al. High-dose dexamethasone versus prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial[J]. Blood,2016,127(3):296-302. doi:10.1182/blood-2015-07-659656.
  • 5WangS, YangR, ZouP, et al. A multicenter randomized controlled trial of recombinant human thrombopoietin treatment in patients with primary immune thrombocytopenia[J]. Int J Hematol,2012,96(2):222-228. doi:10.1007/s12185-012-1124-8.
  • 6BusselJB, ChengG, SalehMN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura[J]. N Engl J Med,2007,357(22):2237-2247. doi:10.1056/NEJMoa073275.
  • 7BusselJB, ProvanD, ShamsiT, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, doubleblind, placebo-controlled trial[J]. Lancet,2009,373(9664):641-648. doi:10.1016/S0140-6736(09)60402-5.
  • 8ChengG, SalehMN, MarcherC, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study[J]. Lancet,2011,377(9763):393-402. doi:10.1016/S0140-6736(10)60959-2.
  • 9SalehMN, BusselJB, ChengG, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study[J]. Blood,2013,121(3):537-545. doi:10.1182/blood-2012-04-425512.
  • 10KuterDJ, BusselJB, LyonsRM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial[J]. Lancet,2008,371(9610):395-403. doi:10.1016/S0140-6736(08)60203-2.

共引文献436

同被引文献30

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部